AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF)

This study has been terminated.

(DSMB recommended terminating for futility; excess mortality in the warfarin treatment group made benefit highly unlikely and created important safety concerns.)

Sponsor:

Collaborator:

Duke Clinical Research Institute

Information provided by (Responsible Party):

National Heart, Lung, and Blood Institute (NHLBI)

ClinicalTrials.gov Identifier:

NCT00957242

First received: August 10, 2009

Last updated: December 9, 2011

Last verified: December 2011

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been terminated.
Study Completion Date:	July 2011
Primary Completion Date:	July 2011 (Final data collection date for primary outcome measure)

No publications provided by National Heart, Lung, and Blood Institute (NHLBI)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA; Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012 Jul 1;186(1):88-95. Epub 2012 May 3.

To Top